Skip to main content
. 2015 Aug 17;33(30):3467–3474. doi: 10.1200/JCO.2014.59.2139

Fig A2.

Fig A2.

Mean (± standard deviation) obinutuzumab serum concentrations in patients with indolent non-Hodgkin lymphoma after once-per-week administration of 1,000 mg obinutuzumab during the four-cycle induction period and during 11 cycles of maintenance regimen, which consisted of once-every-2-months administration of 1,000 mg obinutuzumab. Error bars represent the standard deviation.